Sarah Chamberlain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarah Chamberlain has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Gal Shafirstein
Department of Cell Stress Biology, Photodynamic Therapy Center Roswell Park Comprehensive Cancer Center Buffalo New York USA
2 shared publications Chukwumere Nwogu
Department of Thoracic Surgery Roswell Park 665 Elm St. Buffalo New York 14203
1 shared publication- David A. Bellnier
Roswell Park Cancer Institute (USA)
1 shared publication David Bellnier
Department of Cell Stress Biology, Photodynamic Therapy Center Roswell Park Comprehensive Cancer Center (Roswell Park) 665 Elm St. Buffalo New York 14203
1 shared publicationEmily Oakley
Department of Cell Stress Biology, Photodynamic Therapy Center Roswell Park Comprehensive Cancer Center (Roswell Park) 665 Elm St. Buffalo New York 14203
1 shared publication- Houston D. Cole
Department of Chemistry and Biochemistry
1 shared publication
Latest Publications
- Open Access
- 28 June 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (7) , 137
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC50 of 1.98 μM (J/cm2) and 4807 μM (J/cm2) for green and red light, respectively. Cells were then treated with 10 µM TLD1433 in a 96-well plate with the OSA using two 2-cm radial diffusers, each transmitted 532 nm light at 50 mW/cm for 278 s. Monte Carlo simulations of the surface light propagation from the OSA computed light fluence (J/cm2) and irradiance (mW/cm2) distribution. In regions where 100% loss in cell viability was measured, the simulations suggest that >20 J/cm2 of 532 nm was delivered. Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT.
- 28 June 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (7) , 137
Open AccessTLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC50 of 1.98 μM (J/cm2) and 4807 μM (J/cm2) for green and red light, respectively. Cells were then treated with 10 µM TLD1433 in a 96-well plate with the OSA using two 2-cm radial diffusers, each transmitted 532 nm light at 50 mW/cm for 278 s. Monte Carlo simulations of the surface light propagation from the OSA computed light fluence (J/cm2) and irradiance (mW/cm2) distribution. In regions where 100% loss in cell viability was measured, the simulations suggest that >20 J/cm2 of 532 nm was delivered. Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT.
- 6 October 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 52 (6) , 523-529
An Optical Surface Applicator for Intraoperative Photodynamic Therapy
Background and Objectives: Intraoperative photodynamic therapy (IO‐PDT) is typically administered by a handheld light source. This can result in uncontrolled distribution of light irradiance that impacts tissue and tumor response to photodynamic therapy. The objective of this work was to characterize a novel optical surface applicator (OSA) designed to administer controlled light irradiance in IO‐PDT.Study Design/Materials and Methods: An OSA was constructed from a flexible silicone mesh applicator with multiple cylindrically diffusing optical fibers (CDF) placed into channels of the silicone. Light irradiance distribution, at 665 nm, was evaluated on the OSA surface and after passage through solid tissue‐mimicking optical phantoms by measurements from a multi‐channel dosimetry system. As a proof of concept, the light administration of the OSA was tested in a pilot study by conducting a feasibility and performance test with 665‐nm laser light to activate 2‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) in the thoracic cavity of adult swine.Results: At the OSA surface, the irradiance distribution was non‐uniform, ranging from 128 to 346 mW/cm2. However, in the tissue‐mimicking phantoms, beam uniformity improved markedly, with irradiance ranges of 39–153, 33–87, and 12–28 mW/cm2 measured at phantom thicknesses of 3, 5, and 10 mm, respectively. The OSA safely delivered the prescribed light dose to the thoracic cavities of four swine.Conclusions: The OSA can provide predictable light irradiances for administering a well‐defined and potentially effective therapeutic light in IO‐PDT. Lasers Surg. Med.
- 6 October 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 52 (6) , 523-529
An Optical Surface Applicator for Intraoperative Photodynamic Therapy
Background and Objectives: Intraoperative photodynamic therapy (IO‐PDT) is typically administered by a handheld light source. This can result in uncontrolled distribution of light irradiance that impacts tissue and tumor response to photodynamic therapy. The objective of this work was to characterize a novel optical surface applicator (OSA) designed to administer controlled light irradiance in IO‐PDT.Study Design/Materials and Methods: An OSA was constructed from a flexible silicone mesh applicator with multiple cylindrically diffusing optical fibers (CDF) placed into channels of the silicone. Light irradiance distribution, at 665 nm, was evaluated on the OSA surface and after passage through solid tissue‐mimicking optical phantoms by measurements from a multi‐channel dosimetry system. As a proof of concept, the light administration of the OSA was tested in a pilot study by conducting a feasibility and performance test with 665‐nm laser light to activate 2‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) in the thoracic cavity of adult swine.Results: At the OSA surface, the irradiance distribution was non‐uniform, ranging from 128 to 346 mW/cm2. However, in the tissue‐mimicking phantoms, beam uniformity improved markedly, with irradiance ranges of 39–153, 33–87, and 12–28 mW/cm2 measured at phantom thicknesses of 3, 5, and 10 mm, respectively. The OSA safely delivered the prescribed light dose to the thoracic cavities of four swine.Conclusions: The OSA can provide predictable light irradiances for administering a well‐defined and potentially effective therapeutic light in IO‐PDT. Lasers Surg. Med.